King Pharmaceuticals, Inc.
http://www.kingpharm.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From King Pharmaceuticals, Inc.
Moonlake Aims To Defy The Single-Product Risk
The group is pushing sonelokimab into pivotal trials in two indications and starting from scratch in three more. What comes after that?
Acelyrin PsA Data Are Positive, But Is Its IL-17 Blocker Competitive?
Troubled since a miss in hidradenitis suppurativa last fall, Acelyrin’s izokibep succeeded in a psoriatic arthritis trial, but will the drug compete well against other IL-17 inhibitors?
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
AbbVie Ups Efforts In HS And Advances Lutikizumab Into Phase III
There are a raft of investigational products looking to move into the rapidly growing hidradenitis suppurativa market and AbbVie is hoping to grab a decent share with two assets, the anti-interleukin-1 alpha and beta monoclonal antibody lutikizumab and its anti-inflammatory blockbuster Rinvoq.
Company Information
- Industry
- Medical Devices
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Alpharma Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice